Phase II Study of Everolimus (RAD001, Afinitor(R)) for Children With Recurrent or Progressive Ependymoma
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Ependymoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 25 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 20 Jan 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019 as reported by ClinicalTrials.gov record.